| 86.5 1 (1.17%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 109.05  |
1-year : | 115.12 |
| Resists | First : | 93.36 |
Second : | 98.56 |
| Pivot price | 90.32 |
|||
| Supports | First : | 84.95 |
Second : | 70.68 |
| MAs | MA(5) : | 87.62 |
MA(20) : | 90.55 |
| MA(100) : | 99.25 |
MA(250) : | 101.98 |
|
| MACD | MACD : | -2.3 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 5.8 |
D(3) : | 8.3 |
| RSI | RSI(14): 37.4  |
|||
| 52-week | High : | 124 | Low : | 79.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BNTX ] has closed above bottom band by 15.1%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 87.17 - 87.66 | 87.66 - 88.11 |
| Low: | 83.66 - 84.3 | 84.3 - 84.89 |
| Close: | 85.57 - 86.5 | 86.5 - 87.35 |
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Wed, 10 Jun 2026
How New Lung Cancer Data for Pumitamig Could Reshape BioNTech’s (BNTX) Post-Vaccine Investment Story - simplywall.st
Tue, 09 Jun 2026
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study - Yahoo Finance
Mon, 08 Jun 2026
Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals - Yahoo Finance
Mon, 08 Jun 2026
BioNTech (BNTX) sets up USD 1.0B Nasdaq ADS repurchase program - Stock Titan
Mon, 08 Jun 2026
BioNTech SE (BNTX) Stock Analysis: Unpacking a 39% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Wed, 03 Jun 2026
Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX) - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 253 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 57.5 (%) |
| Held by Institutions | 20 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 3,220 (K) |
| EPS | -5.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 85.9 |
| Profit Margin | -44.7 % |
| Operating Margin | -576.7 % |
| Return on Assets (ttm) | -4.2 % |
| Return on Equity (ttm) | -6.7 % |
| Qtrly Rev. Growth | -35.5 % |
| Gross Profit (p.s.) | 8.73 |
| Sales Per Share | 11.11 |
| EBITDA (p.s.) | -4.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 816 (M) |
| Levered Free Cash Flow | -428 (M) |
| PE Ratio | -14.69 |
| PEG Ratio | 0 |
| Price to Book value | 1 |
| Price to Sales | 7.78 |
| Price to Cash Flow | 26.81 |
| Dividend | 2.1 |
| Forward Dividend | 0 |
| Dividend Yield | 2.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|